Searched for
RANBAXY SHARES
After 50 hearings, court reserves judgement in Daiichi-Fortis caseThe Delhi High Court has reserved its judgment in a significant arbitration case. Japanese drug maker Daiichi Sankyo is seeking to enforce ...- Fortis liability case: Delhi HC says blame can't be shifted to third partyAmid ongoing legal disputes, the Delhi High Court is probing Fortis Healthcare's oversight concerning the sale of shares belonging to the S...
- ED opposes Jacqueline Fernandez's approver plea in Rs 200 crore laundering caseThe Enforcement Directorate has opposed actor Jacqueline Fernandez's request to become an approver in a Rs 200 crore money laundering case....
- Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Ranbaxy shares to stop trading on exchanges from April 6In April, 2014, Sun Pharma had announced it would acquire Ranbaxy in an all-stock transaction worth USD 4 billion that includes $800 millio...
- Sun Pharma denies unit's role in Ranbaxy share run-up before dealSun Pharma said it had "no access to non-public information of Ranbaxy" when its unit Silverstreet bought shares in Ranbaxy.
- Andhra Pradesh High Court puts on hold Sun-Ranbaxy deal till insider trade verdictShares of Ranbaxy, which is majority-owned by Japan’s Daiichi-Sankyo, saw an unusual increase in price and turnover during six trading days...
- Buy Sun Pharma shares through RanbaxyAn investor who is really confident that the deal will go through can buy Ranbaxy shares and pocket the difference when the merger is compl...
- Ranbaxy rallies nearly 10% on $3.2 billion deal with Sun PharmaThe deal values Ranbaxy shares at Rs 457 apiece, representing an 18 per cent premium to their 30-day volume-weighted average share price.
- Ranbaxy shares surge nearly 6% as Q4 net loss narrowsShares of Ranbaxy Laboratories today gained nearly 6 per cent after the company's fourth quarter net loss narrowed to Rs 158.94 crore.
- Quarterly results of Ranbaxy may not be good: Jagdish MalkaniJagdish Malkani, Member NSE & BSE, shares his views on the current situation of Ranbaxy.
- Ranbaxy shares dive over 9% on bourses after Daiichi Sankyo says misled over probesFollowing the news, shares of the company opened the day on a weak note and further tanked 9.3 per cent to Rs 391 on the BSE.
- Ranbaxy shares down over 3% after drug recall in USShares of Ranbaxy today slumped over three per cent on the bourses after the company said it has recalled its cholesterol-lowering drug Ato...
- Ranbaxy Q3 top-line seen up 33% at Rs 2698 croreRanbaxy is expected to report a 33 per cent jump in its net sales for the quarter ended September 30 to Rs 2698 crore.
- Ranbaxy receives USFDA approval for anti acne drug AbsoricaRanbaxy laboratories has received an approval for an anti acne drug Absorica developed by US firm Cipher, the company said in a release to ...
- Ranbaxy, Daiichi say deal's on trackPharma analysts are apprehensive that the investigations against Ranbaxy might impact its product flow to US and its out-of-court settlemen...
- Ranbaxy shares surge on stake sale talksThe Ranbaxy Laboratories scrip rose 6.53% on Tuesday to a 52-week high amid speculation of a possible stake sale by the promoters or a sale...
- Ranbaxy stock slides on raids on US officesThe Ranbaxy share price dropped 5% on Thursday in the backdrop of US federal officials conducting a search on the premises of the company’s...
Load More
